Close

Summit Therapeutics (SMMT) Receives FDA Fast Track Status for DMD Treatment

September 26, 2016 7:03 AM EDT Send to a Friend
Summit Therapeutics plc (NASDAQ: SMMT) received Fast Track designation from the US Food and Drug Administration for ezutromid in the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login